von willebrand factor recombinant

**Von willebrand factor recombinant** is a **recombinant protein therapy** used for patients with **von Willebrand disease (VWD)**, a genetic bleeding disorder characterized by deficiency or dysfunction of the endogenous von Willebrand factor (VWF), which is essential for platelet adhesion and stability of factor VIII in blood clotting. This drug is designed to replace missing or defective VWF, restoring normal platelet adhesion and aggregation, and therefore improving clot formation. Von willebrand factor recombinant has a long half-life and contains ultra-large multimers of VWF similar to those naturally present in human plasma, but not subjected to ADAMTS13 proteolysis prior to use. It is approved for: - On-demand treatment and control of bleeding episodes in adults and children with VWD - Perioperative management of bleeding in these populations - Routine prophylaxis to reduce the frequency of bleeding episodes in adults with VWD (all types), and previously for adults with Type 3 VWD - It is not derived from human or animal plasma but is produced using recombinant DNA technology in CHO (Chinese hamster ovary) cells - Developed and marketed exclusively as VONVENDI, it represents the only FDA-approved recombinant VWF therapy for both adult and pediatric patients with VWD[1][2][3][4][5][6].

Brand names

VONVENDI

Other names

rVWF